Why Is SUMMIT THERAPEUTICS (SMMT) Stock Moving Today?

Why SMMT stock is up today

SUMMIT THERAPEUTICS shares rose 7.44 percent to $17.61 on Tuesday, driven by a major $2 billion investment from AstraZeneca. The deal involves AstraZeneca acquiring convertible preferred shares in Summit Therapeutics, which implies a $18.36 common-stock conversion price based on a five-day volume-weighted average price plus 10 percent. The investment is intended to accelerate the development of ivonescimab, a first-in-class bispecific antibody.

What Happened

The stock opened at $16.44 and reached an intraday high of $17.66 at 11:10 AM ET. The session saw a low of $16.17 at 9:35 AM ET. The price increase followed the announcement of the strategic equity investment by AstraZeneca, which has entered into a clinical collaboration agreement with Summit Therapeutics to evaluate sonesitatug vedotin in combination with ivonescimab. The investment marks a significant vote of confidence in Summit's development pipeline and strengthens its balance sheet.

H.C. Wainwright and Citizens reissued their Neutral stock ratings for Summit Therapeutics following the AstraZeneca deal. Citigroup maintained its Buy rating and raised its price target to $43. The stock is currently trading below the implied conversion price of the AstraZeneca investment, which is seen as a potential catalyst for further gains.

What The Data Shows

The stock traded on 4.0 million shares, which is 0.7 times the 3-month daily average. The session saw two notable options prints, with put premium at $1.9 million and the largest single print at $1.1 million. Over the last eight sessions, the stock declined 3.8 percent from $17.95 to $17.26. On September 30, the stock printed 20 fresh 52-week highs and 8 fresh 52-week lows. The stock currently trades within its 52-week range of $12.07 to $29.23.

What To Watch

Investors will be watching the progress of clinical trials for ivonescimab and the outcomes expected in 2026. These milestones will be critical in determining the long-term value of the investment and the stock's trajectory.

Why is SMMT stock moving today?

SUMMIT THERAPEUTICS (SMMT) is drawing unusual attention today. Our newswire has captured 1 story on SMMT across 1 source in the last 36 hours, with AI sentiment reading mixed (avg 56/100). The most recent driver: "Summit Therapeutics stock rating reaffirmed at Citizens on trial data" (Investing.com Analyst Ratings).

Is SMMT a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of SMMT coverage reads 56/100 over 1 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.